Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories and Pierre Fabre Medicament have released positive top-line results from a double-blind, randomized, placebo-controlled Phase III trial investigating the safety, efficacy and tolerability of levomilnacipran in patients with major depressive disorder (MDD).
Subscribe to our email newsletter
The results of the trial demonstrated that levomilnacipran showed improvement in all dose groups, in comparison to placebo.
Levomilnacipran, a sustained-release formulation, once-daily treatment was well tolerated in the study.
Forest Research Institute R&D president Marco Taglietti said these positive Phase III results are encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder..